GSK increases investment in Relovair development

GlaxoSmithKline has increased its share of Theravance, with which it is developing Relovair fluticasone/vilanterol COPD product, to approximately 19%. In addition, GSK is crediting a UK "patent box" proposal to encourage R&D investments with in announcing its final decision to invest in its facility in Ware, Hertfordshire for the manufacture of the new inhalation device for the product. Read the company’s press release on Theravance and the press release on the "patent box" investments.